Abstract:BACKGROUND: Cardiovascular diseases are the main cause of worldwide morbidity and mortality, highlighting the need for new therapeutic strategies. Autophosphorylation and subsequent overactivation of the cardiac stress-responsive enzyme CaMKIIδ (Ca 2+ /calmodulin-dependent protein kinase IIδ) serves as a central driver of multiple cardiac disorders. METHODS: To develop a comprehensive therapy for heart failure, we used CRISPR-Cas9 adenine base editing to ablate the autophosphorylation site of CaMKIIδ. We generated mice harboring a phospho-resistant CaMKIIδ mutation in the germline and subjected these mice to severe transverse aortic constriction, a model for heart failure. Cardiac function, transcriptional changes, apoptosis, and fibrosis were assessed by echocardiography, RNA sequencing, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, and standard histology, respectively. Specificity toward CaMKIIδ gene editing was assessed using deep amplicon sequencing. Cellular Ca 2+ homeostasis was analyzed using epifluorescence microscopy in Fura-2–loaded cardiomyocytes. RESULTS: Within 2 weeks after severe transverse aortic constriction surgery, 65% of all wild-type mice died, and the surviving mice showed a dramatically impaired cardiac function. In contrast to wild-type mice, CaMKIIδ phospho-resistant gene-edited mice showed a mortality rate of only 11% and exhibited a substantially improved cardiac function after severe transverse aortic constriction. Moreover, CaMKIIδ phospho-resistant mice were protected from heart failure–related aberrant changes in cardiac gene expression, myocardial apoptosis, and subsequent fibrosis, which were observed in wild-type mice after severe transverse aortic constriction. On the basis of identical mouse and human genome sequences encoding the autophosphorylation site of CaMKIIδ , we deployed the same editing strategy to modify this pathogenic site in human induced pluripotent stem cells. It is notable that we detected a >2000-fold increased specificity for editing of CaMKIIδ compared with other CaMKII isoforms, which is an important safety feature. Although wild-type cardiomyocytes showed impaired Ca 2+ transients and an increased frequency of arrhythmias after chronic β-adrenergic stress, CaMKIIδ -edited cardiomyocytes were protected from these adverse responses. CONCLUSIONS: Ablation of CaMKIIδ autophosphorylation by adenine base editing may offer a potential broad-based therapeutic concept for human cardiac disease.

CRISPR-Mediated Activation of Endogenous Gene Expression in the Postnatal Heart

A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9

Direct Cardiac Reprogramming Via Combined CRISPRa-Mediated Endogenous Gata4 Activation and Exogenous Mef2c and Tbx5 Expression

Abstract 15721: CRISPR Activates Heterochromatic Cardiac Genes in Fibroblasts to Initiate Lineage Conversion into Cardiac Progenitors

CRISPR-Cas9 Base Editing of Pathogenic CaMKIIδ Improves Cardiac Function in a Humanized Mouse Model.

Cardiac RNase Z edited via CRISPR-Cas9 drives heart hypertrophy in Drosophila

In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation

In Vivo Reprogramming of Mouse Fibroblasts into Cardiac Progenitor Cells for Myocardial Infarction Treatment

In vivo CRISPR screening identifies RNF20/40 as epigenetic regulators of cardiomyocyte maturation

Engineered Cardiac Tissues as a Platform for CRISPR‐Based Mitogen Discovery

Abstract 210: Reprogramming Mouse Fibroblasts Into Cardiac Progenitor Cells Using Crispr Technique Targeting Endogenic Genes

Abstract 106: Efficient in Vivo Homology-Directed Repair Within Cardiomyocytes

Enhancing stem cell survival in an ischemic heart by CRISPR-dCas9-based gene regulation

Abstract 17091: High Efficient Therapeutic Genome Editing in Cardiovascular Endotheliumby Nanoparticle Delivery of Crispr Plasmid

Elimination of CaMKIIδ Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice

Ablation of CaMKIIδ Oxidation by CRISPR-Cas9 Base Editing As a Therapy for Cardiac Disease

Cardiac Applications of CRISPR/AAV-Mediated Precise Genome Editing

Phase-separated DropCRISPRa platform for efficient gene activation in mammalian cells and mice

CRISPR activation of endogenous genes reprograms fibroblasts into cardiovascular progenitor cells for myocardial infarction therapy

Generation and validation of versatile inducible CRISPRi embryonic stem cell and mouse model

Multiplexed Genome Regulation in Vivo with Hyper-Efficient Cas12a